PITTSBURGH, Jan. 6, 2022 /PRNewswire/ -- Viatris Inc.
(NASDAQ: VTRS) today announced that on Tuesday, January 4, its Board of Directors
approved a 9% increase in its quarterly dividend and declared a
dividend for the first quarter of 2022 of 12 cents
($0.12) per share on outstanding
common stock. At this quarterly dividend rate, subject to the
normal quarterly review by the Board of Directors, the annual
dividend rate for the fiscal year 2022 is 48
cents ($0.48) per share.
The dividend will be payable on March 16, 2022 to
shareholders of record at the close of business on February
24, 2022.
"We have been pleased with our strong underlying business
performance and operational momentum and remain committed to
returning capital to shareholders," said Michael Goettler, Chief Executive Officer of
Viatris.
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare
company, empowering people worldwide to live healthier at every
stage of life. We provide access to medicines, advance sustainable
operations, develop innovative solutions and leverage our
collective expertise to connect more people to more products
and services through our one-of-a-kind Global Healthcare Gateway®.
Formed in November 2020, Viatris
brings together scientific, manufacturing and distribution
expertise with proven regulatory, medical, and commercial
capabilities to deliver high-quality medicines to patients in more
than 165 countries and territories. Viatris' portfolio comprises
more than 1,400 approved molecules across a wide range of
therapeutic areas, spanning both non-communicable and infectious
diseases, including globally recognized brands, complex generic and
branded medicines, a growing portfolio of biosimilars, and a
variety of over-the-counter consumer products. With a global
workforce of approximately 38,000, Viatris is
headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China, and Hyderabad, India. Learn more at
viatris.com and investor.viatris.com, and connect with us on
Twitter
at @ViatrisInc, LinkedIn and YouTube.
Forward Looking Statement
This press release includes
statements that constitute "forward-looking statements." These
statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Such forward
looking statements may include statements that Viatris has declared
a dividend of 12 cents ($0.12) per share of common stock payable on
March 16, 2022 to shareholders of
record at the close of business on February
24, 2022; at this quarterly dividend rate, subject to the
normal quarterly review by the Board of Directors, the annual
dividend rate for the fiscal year 2022 is 48
cents ($0.48) per share; and
that we have been pleased with our strong underlying business
performance and operational momentum and remain committed to
returning capital to shareholders. Because forward-looking
statements inherently involve risks and uncertainties, actual
future results may differ materially from those expressed or
implied by such statements. Factors that could cause or contribute
to such differences include, but are not limited to: the potential
impact of public health outbreaks, epidemics and pandemics,
including the ongoing challenges and uncertainties posed by the
COVID-19 pandemic; the integration of Mylan N.V. and Pfizer Inc.'s
Upjohn business (the "Upjohn Business"), which combined to form
Viatris (the "Combination") and the implementation of our global
restructuring initiatives being more difficult, time consuming or
costly than expected, or being unsuccessful; the ability to achieve
expected benefits, synergies, and operating efficiencies in
connection with the Combination or its restructuring initiatives
within the expected timeframe or at all; actions and decisions of
healthcare and pharmaceutical regulators; changes in healthcare and
pharmaceutical laws and regulations in the U.S. and abroad; any
regulatory, legal or other impediments to Viatris' ability to bring
new products to market, including but not limited to "at-risk"
launches; Viatris' or its partners' ability to develop,
manufacture, and commercialize products; the scope, timing and
outcome of any ongoing legal proceedings, and the impact of any
such proceedings; any significant breach of data security or data
privacy or disruptions to our information technology systems; risks
associated with international operations, including our operations
in China; the ability to protect
intellectual property and preserve intellectual property rights;
changes in third-party relationships; the effect of any changes in
Viatris' or its partners' customer and supplier relationships and
customer purchasing patterns; the impacts of competition; changes
in the economic and financial conditions of Viatris or its
partners; uncertainties and matters beyond the control of
management; and the other risks Viatris' filings with the
Securities and Exchange Commission (SEC). Viatris routinely uses
its website as a means of disclosing material information to the
public in a broad, non-exclusionary manner for purposes of the
SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no
obligation to update these statements for revisions or changes
after the date of this release other than as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viatris-announces-9-dividend-increase-fourth-consecutive-quarterly-dividend-301455089.html
SOURCE Viatris Inc.